Sichuan Biokin Pharmaceutical Co.,Ltd. (SHA:688506)
China
· Delayed Price · Currency is CNY 236.99
+12.11 (5.39%)
Last updated: Mar 28, 2025
SHA:688506 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | 3,708 | -780.5 | -282.38 | -99.99 | 37.9 | Upgrade
|
| Depreciation & Amortization | 79.59 | 64.28 | 62.94 | 53.14 | 49.31 | Upgrade
|
| Other Amortization | 3.34 | 2.75 | 1.79 | 1.08 | 1.2 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0 | -0.15 | 0.02 | -0.01 | - | Upgrade
|
| Asset Writedown & Restructuring Costs | 8.13 | 0.29 | 0.46 | 6.13 | 0.9 | Upgrade
|
| Loss (Gain) From Sale of Investments | -19.23 | -0 | - | -3.14 | -2.54 | Upgrade
|
| Provision & Write-off of Bad Debts | - | -6.65 | 7.58 | -3 | -2.02 | Upgrade
|
| Other Operating Activities | 54.88 | 40.74 | 27.79 | 9.45 | 9.6 | Upgrade
|
| Change in Accounts Receivable | 275.68 | 73.6 | -142.62 | 62.89 | 78.12 | Upgrade
|
| Change in Inventory | -42.14 | -52.56 | -23.96 | -22.22 | 10.44 | Upgrade
|
| Change in Accounts Payable | 70.92 | 35.92 | 107.12 | -121.61 | -92.57 | Upgrade
|
| Change in Other Net Operating Assets | 21.07 | -0.04 | 0.03 | -0.06 | -0.04 | Upgrade
|
| Operating Cash Flow | 4,059 | -615.35 | -258.65 | -135.03 | 78.46 | Upgrade
|
| Operating Cash Flow Growth | - | - | - | - | 180.30% | Upgrade
|
| Capital Expenditures | -83.86 | -81.94 | -34.56 | -44.6 | -15.37 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.1 | 0.06 | 0.01 | 0.07 | 0.03 | Upgrade
|
| Investment in Securities | - | -20.05 | - | 197.2 | - | Upgrade
|
| Other Investing Activities | -2,482 | 20.05 | - | 3.48 | -194.66 | Upgrade
|
| Investing Cash Flow | -2,565 | -81.88 | -34.55 | 156.15 | -210 | Upgrade
|
| Long-Term Debt Issued | 1,904 | 447.7 | 467.54 | 302 | 150 | Upgrade
|
| Long-Term Debt Repaid | -518.96 | -312.94 | -220.82 | -184.21 | -194.73 | Upgrade
|
| Net Debt Issued (Repaid) | 1,385 | 134.76 | 246.72 | 117.79 | -44.73 | Upgrade
|
| Issuance of Common Stock | - | - | 907.47 | - | - | Upgrade
|
| Common Dividends Paid | -38.36 | -18.77 | -12.59 | -26.97 | -9.96 | Upgrade
|
| Other Financing Activities | -72.72 | -25.14 | -2.19 | -2.16 | -10.06 | Upgrade
|
| Financing Cash Flow | 1,274 | 90.84 | 1,139 | 88.66 | -64.76 | Upgrade
|
| Foreign Exchange Rate Adjustments | 49.19 | -2.62 | 0.26 | -0.76 | -2.01 | Upgrade
|
| Net Cash Flow | 2,816 | -609 | 846.47 | 109.01 | -198.31 | Upgrade
|
| Free Cash Flow | 3,975 | -697.29 | -293.21 | -179.63 | 63.09 | Upgrade
|
| Free Cash Flow Growth | - | - | - | - | 807.17% | Upgrade
|
| Free Cash Flow Margin | 68.26% | -124.10% | -41.69% | -22.55% | 6.23% | Upgrade
|
| Free Cash Flow Per Share | 9.92 | -1.74 | -0.81 | -0.50 | 0.18 | Upgrade
|
| Cash Income Tax Paid | 428.2 | 48.98 | 36.6 | 101.05 | 127.36 | Upgrade
|
| Levered Free Cash Flow | 194.39 | -396 | -145.1 | -135.4 | 65.39 | Upgrade
|
| Unlevered Free Cash Flow | 194.39 | -380.58 | -131.05 | -129.97 | 70.12 | Upgrade
|
| Change in Net Working Capital | 2,144 | -125.18 | -44.92 | 39.88 | -49.27 | Upgrade
|
Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.